ArticleChemMedChem2026
Hit-To-Lead Optimization of a Pyridylpiperazine Class Against Malaria: Pharmacokinetic Profile and In Vivo Efficacy of Optimized Compounds.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Malaria remains a significant global health challenge caused by Plasmodium parasites. Current antimalarial treatment strategies face mounting challenges due to the rapid development of drug resistance. This work aimed at the hit-to-lead optimization of a pyridylpiperazine class by evaluating the in vitro pharmacokinetic profile and the in vivo efficacy and safety against malaria. The systematic in vitro assessment of ADME properties for 10 previously selected bioactive compounds enabled a detailed structure-ADME relationship analysis. This process highlighted compounds 7 and 9 as having the most promising profiles for improved bioavailability. These optimized compounds were then tested in an in vivo murine model of malaria, and reduced the likelihood of mice developing cerebral malaria. Compound 7 emerged as the most effective, reducing parasitemia by up to 91.7%. These results successfully validate that chemical modifications to the toluyl fragment of the initial hit optimized the pharmacodynamic and pharmacokinetic parameters, yielding two candidates with suitable ADME profiles and proven in vivo efficacy against malaria. This work supports the further development of the pyridylpiperazine class against malaria and highlights the need to explore modifications on other parts of the molecular scaffold and elucidate their mechanism of action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.